{"groups":[{"description":"Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle until the documentation of confirmed progressive disease (PD), intolerable toxicity, death, withdrawal of participation in the study/consent, lost to follow-up, or as long as they benefited from therapy according to the opinion of the responsible study investigator.","id":"FG000","title":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"504"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"57"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"52"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"31"}],"type":"Miscellaneous"},{"reasons":[{"groupId":"FG000","numSubjects":"21"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Transition to Commercial Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Participants Did Not Receive Study Drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"682"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"676"}],"type":"Received Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Completed = did not discontinue treatment\n\nNote: \"Reason for Not Completed\" below equates to \"Reason for Treatment Discontinuation\"","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"682"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Study participants had to have either refractory or relapsed and refractory disease, defined as documented disease progression during or within 60 days of completing their last myeloma therapy to be eligible to participate in the trial.","recruitmentDetails":"The study was conducted at 112 sites: 4 in Austria, 7 in Belgium, 3 in Denmark, 1 in Estonia, 2 in Finland, 13 in France, 17 in Germany, 1 in Greece, 3 in Ireland, 15 in Italy, 5 in the Netherlands, 2 in Norway, 3 in Poland, 4 in Portugal, 1 in Slovakia, 15 in Spain, 2 in Sweden, 3 in Switzerland, 2 in Turkey, and 9 in the United Kingdom."}